Author:
Ceriello Antonio,Rodbard Helena W.,Battelino Tadej,Brosius Frank,Cosentino Francesco,Green Jennifer,Ji Linong,Kellerer Monika,Koob Susan,Kosiborod Mikhail,Lalic Nebojsa,Marx Nikolaus,Nedungadi T. Prashant,Parkin Christopher G.,Rydén Lars,Sheu Wayne Huey-Herng,Standl Eberhard,Vandvik Per Olav,Schnell Oliver,
Abstract
AbstractIn recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism